Preclinical and clinical data show that the PDE5 inhibitor tadalafil enhanced the immune response in head and neck squamous cell carcinoma (HNSCC) patients through inhibition of MDSCs (NCT01697800) (352). The gene discussed is PDE5A; the disease is head and neck squamous cell carcinoma.